Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Swetha Kambhampati, Matthew Mei, Lu Chen, Sandrine Puverel, Robert Chen, Leslie L. Popplewell, Liana Nikolaenko, Lacolle Peters, Saro H. Armenian, Larry W. Kwak, Steve T Rosen, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 9418–9419.

https://doi.org/10.1182/blood-2022-157623

Published: 2022

Journal Articles

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1065–1067.

https://doi.org/10.1182/blood-2022-165699

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Tanya Siddiqi, Xiuli Wang, M. Suzette Blanchard, Jamie Wagner, Vibhuti Vyas, Mary C. Clark, Sandra Thomas, Baishakhi Barva, Angelica Gamez, Leslie L. Popplewell, Alex F. Herrera, Elizabeth Budde, Liana Nikolaenko, Christine E Brown, Stephen J Forman

Blood (2021) 138 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2021-147082

Published: 2021

Journal Articles

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

Liana Nikolaenko, Carolyn Mulroney, Peter A. Riedell, Ian W. Flinn, Jose Carlos Cruz, Rakhee Vaidya, Koen van Besien, Michael Emde, Vadim Klyushnichenko, Jonathan Strauss, Eduardo Laborda, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young

Blood (2021) 138 (Supplement 1): 2822.

https://doi.org/10.1182/blood-2021-151727

Published: 2021

Journal Articles

EBV Positive DLBCL Is Effectively Treated with Commercial CAR T Cell Therapy but Is Associated with Higher Rates of Severe Immune Effector Cell Associated Neurologic Syndrome (ICANS): A Single Institution Experience

Liana Nikolaenko, Alex F. Herrera, Elizabeth Budde, Joo Y. Song, Geoffrey Shouse

Blood (2021) 138 (Supplement 1): 3862.

https://doi.org/10.1182/blood-2021-153260

Published: 2021

Journal Articles

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Blood (2021) 138 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2021-154187

Published: 2021

Journal Articles

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Liana Nikolaenko, Timothy Pardee, Raphel Steiner, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, Ildefonso Rodriguez-Rivera, David J. Straus, Sanjeev Luther, Ariela Noy

Blood (2021) 138 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2021-153662

Published: 2021

Journal Articles

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Alex F. Herrera, Lu Chen, L. Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Steven T. Rosen, Stephen J Forman, Leslie L. Popplewell, Larry W. Kwak, Matthew Mei

Blood (2021) 138 (Supplement 1): 234.

https://doi.org/10.1182/blood-2021-150031

Published: 2021

Journal Articles

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Tingting Liu, Fei Xu, Elana Thieme, Vi Lam, Guang Fan, MD PhD, Liana Nikolaenko, MD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Olga Danilova, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-134951

Published: 2020

Journal Articles

Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Geoffrey Shouse, DO, PhD, Thai Cao, MD, Jianying Zhang, Matthew Mei, MD, Alex F. Herrera, MD, Liana Nikolaenko, MD, Jasmine Zain, MD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD FACP, Stephen J. Forman, MD, Lihua E Budde, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-143353

Published: 2020

Journal Articles

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, NI-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 4623.

https://doi.org/10.1182/blood-2019-131357

Published: 2019

Journal Articles

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Robert W. Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, Matthew Mei, MD, Leslie L. Popplewell, MD FRCPA, Auayporn P. Nademanee, MDBS, Liana Nikolaenko, MD, Kathryn McBride, Ricardo Ortega, Joo Y. Song, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Stephen J Forman, MD, Hun Ju Lee, MD

Blood (2019) 134 (Supplement_1): 239.

https://doi.org/10.1182/blood-2019-123162

Published: 2019

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tanya Siddiqi, MD, Xiuli Wang, PhD, Joycelynne Palmer, PhD, Leslie L. Popplewell, MD FRCPA, Liana Nikolaenko, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Laura Lim, Vibhuti Vyas, MS, Christine E Brown, PhD, Stephen J. Forman, MD

Blood (2019) 134 (Supplement_1): 4075.

https://doi.org/10.1182/blood-2019-123765

Published: 2019

Journal Articles

Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT)

Zahra Eftekhari, MS, Sally Mokhtari, PhD, Tushondra Thomas, MSN, MBA, PHN, RN-BC, Dongyun Yang, PhD, Liana Nikolaenko, MD, Deron Johnson, PharmD, Jana Dickter, MD, Justine Abella Ross, PharmD, Bernard Tegtmeier, PhD D(ABMM), CIC, Eileen P. Smith, MD, Monzr M. Al Malki, MD, Ricardo Spielberger, MD, Anna B Pawlowska, MD, Argelia Sandoval, MD, John Zaia, MD, Stephen J Forman, MD, Janet Munu, BSc, MBA, RN, Sanjeet Dadwal, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 4477.

https://doi.org/10.1182/blood-2019-130926

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

NARROW

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)

EBV Positive DLBCL Is Effectively Treated with Commercial CAR T Cell Therapy but Is Associated with Higher Rates of Severe Immune Effector Cell Associated Neurologic Syndrome (ICANS): A Single Institution Experience

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT)

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only